Anavex life sciences reports publication in medical journal signifying continued commitment for improvement of the rett syndrome caregiver outcome measure rsbq

New york, june 12, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced the publication of a relevant new peer-reviewed study in the american journal on intellectual and developmental disabilities, entitled ‘rett syndrome behaviour questionnaire in children and adults with rett syndrome: psychometric characterization and revised factor structure'. 1
AVXL Ratings Summary
AVXL Quant Ranking